PLACE OF THIS DOCUMENT IN THE VIEN GUT DOSSIER

Document B.5 does not describe one single disease, and it is not a detailed treatment guide for each accompanying condition. B.5 is the closing document of Part B — the Operating Model. Its role is to define the place of enabling conditions and the principles of priority when several severe chronic diseases are present in one patient at the same time. If B.1 explains how the system is activated, B.2 explains the phase-based treatment plan, B.3 explains the necessary and sufficient conditions for the window of opportunity, and B.4 explains the patient-side participation capacity, then B.5 answers the last question of Group B: when several serious diseases act together, conflict with one another, and narrow the safety margin, how should the system set priorities so that the four validation targets can still remain possible.

Within the multi-layer architecture of the dossier, B.5 belongs to Layer 1 — Basic Architecture. It is also the direct bridge from Part B to Part C. Part C can only work in real life if enabling conditions are controlled well enough to keep the window of opportunity open. If these conditions are not controlled, and if disease–disease and drug–disease conflicts are not resolved, then crystal-free status, delayed dialysis, fewer heart-failure decompensations, and hepatic recompensation are unlikely to become lasting outcomes. This is why B.5 appears at the end of Group B: it gathers the earlier operating logic and brings it to the deepest level of clinical prioritization.

ABSTRACT

B.5 makes one central argument: in patients with complex chronic multimorbidity, the accompanying diseases should not be seen simply as “comorbidities” sitting next to the main disease. They should be seen as enabling conditions — operating conditions that determine whether the model’s four validation targets are still realistically achievable. International evidence shows that complex multimorbidity is now a global reality, while modern guidelines and the evidence hierarchy are still mainly built around single diseases. As a result, the sickest patients often fall outside the true coverage of the guidelines, are excluded from many RCTs, and must be treated inside a structural HOW gap. B.5 describes that gap at the operating level: when several diseases are present together, they do not simply add up — they amplify one another through pathological loops, functional decline, and drug–disease conflicts.

On that basis, B.5 defines enabling conditions as an interconnected system rather than a list of separate diagnoses. It builds a matrix for resolving disease–disease and drug–disease conflicts, proposes priority rules across disease axes, summarizes the minimum safe control thresholds drawn from updated guidelines, and states the central hypothesis of the Vien Gut Model: if HOW and DATA-to-operate are structured tightly enough to resolve conflicts and support longitudinal follow-up, then the window of opportunity for conservative outpatient treatment can stay open wider and longer than in usual care for complex chronic multimorbidity. The anonymized cases DTH and LAU are presented as the most extreme boundary cases that the model can still keep in outpatient care, and three of the four validation targets — delayed dialysis, reduced cardiovascular decompensation, and hepatic recompensation — are proposed as future topics for multicenter validation.